Sanofi SNY and Roche RHHBY announced their fourth-quarter and full-year 2024 results. Novo Nordisk’s NVO novel obesity ...

SNY and RHHBY announce fourth-quarter earnings. NVO's novel obesity medicine, amycretin, shows superior weight loss in study.

DeepSeek rattles Nvidia, OpenAI, and everyone else in the game. Plus, Frontier and Spirit work it out, Elon gets testy, and ...

With thousands of press releases published each week, it can be difficult to keep up with everything on PR Newswire. To help ...

Novo Nordisk Foundation granted DKK 10 billion to benefit people and the planet in milestone year: Denmark Friday, January 31, 2025, 16:00 Hrs [IST] In 2024, on its 100th annivers ...

Novo Nordisk A/S investors got a much-needed boost from last week’s trial results for an experimental weight-loss shot. But ...

With (almost) no fees and unlimited refunds for ATM charges, Novo business checking is a good option for small-business owners on the go. But Novo’s customer support is lacking, and you can’t ...

The FDA’s approval of Ozempic to battle chronic kidney disease “allows us to more broadly address conditions within cardiovascular-kidney-metabolic syndrome, which affects millions of ...